RT Journal Article
SR Electronic
T1 Infection control, occupational and public health measures including mRNA-based vaccination against SARS-CoV-2 infections to protect healthcare workers from variants of concern: a 14-month observational study using surveillance data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.21.21257600
DO 10.1101/2021.05.21.21257600
A1 Yassi, Annalee
A1 Grant, Jennifer M.
A1 Lockhart, Karen
A1 Barker, Stephen
A1 Sprague, Stacy
A1 Okpani, Arnold I.
A1 Wong, Titus
A1 Daly, Patricia
A1 Henderson, William
A1 Lubin, Stan
A1 Sing, Chad Kim
YR 2021
UL http://medrxiv.org/content/early/2021/05/25/2021.05.21.21257600.abstract
AB Background We evaluated measures to protect healthcare workers (HCWs) in Vancouver, Canada, where variants of concern (VOC) went from <1% in February 2021 to >92% in mid-May. Canada has amongst the longest periods between vaccine doses worldwide, despite Vancouver having the highest P.1 variant rate outside Brazil.Methods With surveillance data since the pandemic began, we tracked laboratory-confirmed SARS-CoV-2 infections, positivity rates, and vaccine uptake in all 25,558 HCWs in Vancouver Coastal Health, by occupation and subsector, and compared to the general population. We employed Cox regression modelling adjusted for age and calendar-time to calculate vaccine effectiveness (VE) against SARS-CoV-2 in fully vaccinated (≥ 7 days post-second dose), partially vaccinated (14 days post vaccine) and unvaccinated HCWs; we also compared with unvaccinated community members of the same age-range.Findings Only 3.3% of our HCWs became infected, mirroring community rates, with peak positivity of 9.1%, compared to 11.8% in the community. As vaccine coverage increased, SARS-CoV-2 infections declined significantly in HCWs, despite a surge with predominantly VOC; unvaccinated HCWs had an infection rate of 1.3/10,000 person-days compared to 0.89 for HCWs post first dose, and 0.30 for fully vaccinated HCWs. VE compared to unvaccinated HCWs was 37.2% (95% CI: 16.6-52.7%) 14 days post-first dose, 79.2% (CI: 64.6-87.8%) 7 days post-second dose; one dose provided significant protection against infection until at least day 42. Compared with community infection rates, VE after one dose was 54.7% (CI: 44.8-62.9%); and 84.8% (CI: 75.2-90.7%) when fully vaccinated.Interpretation Predominantly droplet-contact precautions, with N95s required for aerosol generating medical procedures and available as needed according to point-of-care risk assessment, has been a highly effective approach to preventing occupational infection in HCWs, with one dose of mRNA vaccination further reducing infection risk despite VOC and transmissibility concerns. Delaying second doses to allow more widespread vaccination against severe disease, with strict public health, occupational health and infection control measures, has been effective in protecting the healthcare workforce.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was received from the Canadian Institutes of Health Research (CIHR) and the International Development Research Centre (IDRC) through the rapid research funding opportunity from CIHR under PI Yassi and grant, Protecting healthcare workers from COVID-19: A comparative contextualized analysis. The work is also supported and funded by Doctors of BC and Vancouver Coastal Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was provided by the Behavioural Ethics Review Board at the University of British Columbia under certificate H21-01138.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for this study is available at https://innovation.ghrp.ubc.ca/covid19/data-2021.05.17.xlsx https://innovation.ghrp.ubc.ca/covid19/data-2021.05.17.xlsx